Nav: Home

It's time to consider propranolol as an anti-cancer drug, researchers say

October 13, 2016

Propranolol, a beta-blocker commonly prescribed to treat irregular heart rates and other conditions, has significant anti-cancer properties, say researchers in a new clinical study published in ecancermedicalscience.

The Repurposing Drugs in Oncology (ReDO) project, an international collaboration between the Anticancer Fund, Belgium, and US based GlobalCures, says that existing and widely-used non-cancer drugs may represent a relatively untapped source of novel therapies for cancer.

Historically, pharmaceutical companies devote little time to "repurposing" existing drugs. The ReDO project hopes to change that, raising awareness by publishing a series of articles in ecancer to share evidence for using these therapies in cancer medicine.

Propranolol is the latest in a series of drugs that could offer cheap, safe and effective solutions to cancer. It's available globally in generic form and is on the WHO List of Essential Medicines - particularly in angiosarcoma, a rare form of heart cancer.

"The evidence to date in angiosarcoma is especially compelling," says study author Pan Pantziarka, PhD, of the Anticancer Fund, Belgium. "Here is a rare disease with high unmet needs that is unlikely to attract investment from the commercial drug development sector. Propranolol offers these patients evidence of efficacy and with little or no toxicity."

"Existing animal and human data on the use of propranolol to treat cancer is tantalizing and merits rapid and careful evaluation in a number of tumour types," adds study author Vikas P. Sukhatme of Global Cures, Harvard Medical School, USA.

The paper also highlights the potential of propranolol to act on multiple points of the metastatic cascade - particularly in the peri-operative setting. Post-surgical metastatic spread is a widespread clinical phenomenon, and tackling this has huge potential to lead to improved outcomes.

"There is good in vivo evidence that propranolol, alone and in combination with other agents, impacts this process," says Pantziarka. "Reducing metastatic spread ultimately saves lives."

Gauthier Bouche, Medical Director of the Anticancer Fund, points out that propranolol has already been repurposed to treat childhood benign tumours.

"An effective treatment against infantile hemangioma had existed since the 1960s but we only discovered this in 2008 when careful clinicians found it serendipitously. Every day I ask myself: 'what else can propranolol offer to patients with unmet needs?' I think there is a lot, and we shouldn't have to wait another forty years to find out."
-end-
The researchers hope that increased awareness will bring these medications out of the medicine cabinet - and possibly into cancer care.

Read the paper here: http://ecancer.org/journal/10/680-repurposing-drugs-in-oncology-redo-propranolol-as-an-anti-cancer-agent.php

REFERENCE

Pantziarka Pan, Bouche Gauthier, Sukhatme Vidula, Meheus Lydie, Rooman Ilse and Sukhatme Vikas P (2016) Repurposing Drugs in Oncology (ReDO)--Propranolol as an anti-cancer agent ecancer 10 680

ecancermedicalscience

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Anthropomorphic
Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#SB2 2019 Science Birthday Minisode: Mary Golda Ross
Our second annual Science Birthday is here, and this year we celebrate the wonderful Mary Golda Ross, born 9 August 1908. She died in 2008 at age 99, but left a lasting mark on the science of rocketry and space exploration as an early woman in engineering, and one of the first Native Americans in engineering. Join Rachelle and Bethany for this very special birthday minisode celebrating Mary and her achievements. Thanks to our Patreons who make this show possible! Read more about Mary G. Ross: Interview with Mary Ross on Lash Publications International, by Laurel Sheppard Meet Mary Golda...